Compile Data Set for Download or QSAR
Report error Found 86 Enz. Inhib. hit(s) with all data for entry = 12542
TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708330(US20240423977, Example II-7)
Affinity DataIC50: 3.57nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708319(US20240423977, Example I-13)
Affinity DataIC50: 4.81nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708369(US20240423977, Example I-51)
Affinity DataIC50: 5.33nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708331(US20240423977, Example II-20)
Affinity DataIC50: 5.5nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708324(US20240423977, Example II-10)
Affinity DataIC50: 7.45nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708333(US20240423977, Example I-7)
Affinity DataIC50: 8.10nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708340(US20240423977, Example I-19)
Affinity DataIC50: 8.10nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708323(US20240423977, Example II-6)
Affinity DataIC50: 8.20nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708365(US20240423977, Example I-47)
Affinity DataIC50: 9.17nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708360(US20240423977, Example I-42)
Affinity DataIC50: 10.2nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708343(US20240423977, Example I-23)
Affinity DataIC50: 10.2nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708326(US20240423977, Example II-13)
Affinity DataIC50: 10.5nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708322(US20240423977, Example II-5)
Affinity DataIC50: 11nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708315(US20240423977, Example I-2)
Affinity DataIC50: 11nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708328(US20240423977, Example II-17)
Affinity DataIC50: 11nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708332(US20240423977, Example I-5)
Affinity DataIC50: 11.3nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708338(US20240423977, Example I-16)
Affinity DataIC50: 11.6nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708372(US20240423977, Example I-54)
Affinity DataIC50: 11.6nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708356(US20240423977, Example I-36)
Affinity DataIC50: 12.4nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708348(US20240423977, Example I-28)
Affinity DataIC50: 12.5nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708370(US20240423977, Example I-52)
Affinity DataIC50: 13.3nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708367(US20240423977, Example I-49)
Affinity DataIC50: 13.4nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708327(US20240423977, Example II-16)
Affinity DataIC50: 14nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708358(US20240423977, Example I-38)
Affinity DataIC50: 14.1nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708325(US20240423977, Example II-12)
Affinity DataIC50: 14.2nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708316(US20240423977, Example I-3)
Affinity DataIC50: 16nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708320(US20240423977, Example II-1)
Affinity DataIC50: 16.4nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708337(US20240423977, Example I-14)
Affinity DataIC50: 16.6nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708362(US20240423977, Example I-44)
Affinity DataIC50: 17nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708344(US20240423977, Example I-24)
Affinity DataIC50: 17.4nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708364(US20240423977, Example I-46)
Affinity DataIC50: 17.7nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708380(US20240423977, Example I-62)
Affinity DataIC50: 19nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708366(US20240423977, Example I-48)
Affinity DataIC50: 19.2nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708321(US20240423977, Example II-4)
Affinity DataIC50: 20nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708345(US20240423977, Example I-25)
Affinity DataIC50: 20.4nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708361(US20240423977, Example I-43)
Affinity DataIC50: 20.7nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708382(US20240423977, Example I-64)
Affinity DataIC50: 22.7nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708341(US20240423977, Example I-20)
Affinity DataIC50: 23.6nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708335(US20240423977, Example I-10)
Affinity DataIC50: 24nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708350(US20240423977, Example I-30)
Affinity DataIC50: 24nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708342(US20240423977, Example I-22)
Affinity DataIC50: 25nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708384(US20240423977, Example I-66)
Affinity DataIC50: 25.3nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708318(US20240423977, Example I-8)
Affinity DataIC50: 25.9nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708314(US20240423977, Example I-1)
Affinity DataIC50: 26nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708383(US20240423977, Example I-65)
Affinity DataIC50: 26.3nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708353(US20240423977, Example I-33)
Affinity DataIC50: 26.5nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708377(US20240423977, Example I-59)
Affinity DataIC50: 27.3nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708357(US20240423977, Example I-37)
Affinity DataIC50: 29.9nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708346(US20240423977, Example I-26)
Affinity DataIC50: 30nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetInterleukin-1 receptor-associated kinase 4(Human)
Hangzhou Polymed Biopharmaceuticals

US Patent
LigandPNGBDBM708339(US20240423977, Example I-17)
Affinity DataIC50: 31nMAssay Description:1) IRAK4 kinase was dissolved in kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM DTT and 0.01% Brij-35) to a final concentration of 6 nM.[0542]2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

Displayed 1 to 50 (of 86 total ) | Next | Last >>
Jump to: